{
    "id": "449a0b4a-0bc7-4f1b-af1f-d0111a14b44c",
    "time": "2020-08-28T16:50:53Z",
    "source": ["aws.events"],
    "detail-type": "Scheduled Event",
    "region": "us-east-1",
    "event_bus_name": "regintel_custom_event_bus",
    "detail": {
        "data":{
            "s3_enrich_in":"",
            "s3_raw":""
        },
        "metadata": [
            {
                "last_updated": "2020-08-28",
                "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/004782s176lbl.pdf",
                "file_name": "004782s176lbl.pdf",
                "data_source": "FDA/EMA",
                "drug_name": "PREMARIN",
                "active_substance": [
                    "ESTROGENS, CONJUGATED"
                ],
                "strength": [
                    "0.625MG",
                    "0.45MG",
                    "2.5MG",
                    "1.25MG",
                    "0.9MG",
                    "0.3MG"
                ],
                "dosage_form": [
                    "TABLET;ORAL",
                    "CAPSULE"
                ],
                "therapeutic_area": "Hypertension",
                "therapeutic_indication": "Treatment of essential hypertension in adults.Rasilez HCT is indicated in                                           patients whose blood pressure is not adequately controlled on aliskiren                                             or hydrochlorothiazide used alone.Rasilez HCT is indicated as                                                       substitution therapy in patients adequately controlled with aliskiren and                                           hydrochlorothiazide, given concurrently, at the same dose level as in the                                           combination.",
                "year_of_authorization": "2003-07-16",
                "license_holder": "Eli Lilly",
                "route_of_administration": [
                    "ORAL",
                    "CAPSULE"
                ],
                "submission_date_for_initial_approval": "2012-12-23",
                "approval_type": [
                    "NCE or NME",
                    " "
                ],  
                "document_type": "BLA/NDA",  
                "approval_status": "Approved/WithDrawn",  
                "orphan_designation": "Orphan",
                "fda_data": {
                    "application_no": 4782,
                    "submission_type_id": 1,
                    "submission_type_desc":"SUPPL/ORIG",
                    "submission_status": "AP",
                    "submission_no": 124,
                    "submission_class_code": "LABELING",
                    "submission_status_date": "2020-3-20",
                    "sponsor_name": "Eli Lilly",
                    "review_priority": "STANDARD",
                    "products": [
                        {
                            "marketing_status": "Discontinued",
                            "reference_standard": "No",
                            "active_ingredients": [
                                {
                                    "strength":"50MG Base",
                                    "name": "DOXYCYCLINE"
                                }
                            ],
                            "reference_drug": "No",
                            "product_number": "001",
                            "dosage_form": "CAPSULE"
                        },
                        {
                            "marketing_status": "Discontinued",
                            "route": "CAPSULE",
                            "reference_standard": "Yes",
                            "active_ingredients": [
                                {
                                    "strength": "50MG Base",
                                    "name": "DOXYCYCLINE"
                                }
                            ],
                            "reference_drug": "YES",
                            "product_number":"002",
                            "dosage_form": "CAPSULE" 
                        }
                    ]
                },
                "ema_data": {
                    "agency_no": 232,
                    "biosimiliar": "no",
                    "generic": "no",
                    "conditional_approval": "yes",
                    "exceptional_circumstances": "no",
                    "accelerated_assessment": "no",
                    "exceptional_circumstance": "yes",
                    "revision_date":"2020-02-20",
                    "international_non_proprietary_name": "paliperidone",
                    "anatomical_therapeutic_chemical_atc_code": "N05AX13",
                    "revision": 2,
                    "contact_address": "",
                    "pharmacotherapeutic_group": "Psycholeptics, " 
                }
            }
        ]
    }
}